OR502

Phase 2Small molecule

OOncoResponse, Inc.

OR502 is one of 5 small molecule programs targeting Monoclonal. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MonoclonalRecruiting

MonoclonalPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Monoclonal

#DrugCompanyPhaseTrials

Libtayo

Regeneron

Phase 2

2 2

Rabies Vaccine

Novartis

Phase 2

1 3

OR502

OOncoResponse, Inc.

Phase 2

1 4

Human Rabies Immunoglobulin(hrig)

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase 2

1 5

VYD2311

IInvivyd, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Monoclonal

NCT06090266

Clinical

Trials by Indication[1]

Monoclonal1 trial

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Recruiting·OOncoResponse, Inc.·Phase 1/2·NCT06090266·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OR502. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OR502 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OR502. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OncoResponse, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOncoResponse, Inc.

OR502

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Monoclonal1 trial

References

Drug Info

Quick Facts

Related News